A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community
Identifieur interne : 000B68 ( Pmc/Curation ); précédent : 000B67; suivant : 000B69A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community
Auteurs : John Oxford [Royaume-Uni] ; Shobana Balasingam [Royaume-Uni] ; Rob Lambkin [Royaume-Uni]Source :
- Journal of Antimicrobial Chemotherapy [ 0305-7453 ] ; 2004.
Abstract
Influenza A and B viruses cause serious medical problems and social disruption every year in particular countries of the world. The virus is notoriously fickle and may attack citizens in say two adjacent countries but not the third. More rarely a global pandemic virus emerges causing millions of deaths worldwide. The SARS outbreak has illuminated weaknesses in planning for sudden outbreaks of disease in a modern society and in particular how panic can grip and cause intense economic disruption. Many communities in the world are neither prepared for a global pandemic nor a very acute epidemic of influenza. The neuraminidase inhibitors (NAIs) are a new class of antiviral drug targeting a viral influenza enzyme, the neuraminidase, which acts both to facilitate virus infection of cells by clearing a passage through otherwise protective respiratory fluids and also by helping release of the virus by cutting the chemical umbilical cord which links up the virus to the infected cell. Extensive laboratory studies of the two molecules zanamivir and oseltamivir have shown that they block all influenza A and B viruses yet tested and would, in theory, even inhibit the 1918 pandemic virus. Both drugs can be used prophylactically to prevent spread of infection in families and communities where 80–90% protection has been documented. The therapeutic effects are also strong in adults and children abbreviating infection, reducing quantities of excreted virus and reducing antibiotic prescriptions. The drugs have to be taken within 48 h of the onset of symptoms. Drug resistance is not a problem at present because although such mutants occur the mutants are compromised and are less virulent than their drug-sensitive parents and they spread less easily. The two drugs could be stockpiled to prepare for an influenza pandemic but, importantly, clinical and scientific experience need to be gained by using these inhibitors in the yearly conflagrations of epidemic influenza, which unchecked do great harm to our communities.
Url:
DOI: 10.1093/jac/dkh037
PubMed: 14688047
PubMed Central: 7110053
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000B68
Links to Exploration step
PMC:7110053Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community</title>
<author><name sortKey="Oxford, John" sort="Oxford, John" uniqKey="Oxford J" first="John" last="Oxford">John Oxford</name>
<affiliation wicri:level="1"><nlm:aff id="d297587e98">Barts and The London, Retroscreen Virology Ltd, Queen Mary’s School of Medicine and Dentistry, 327 Mile End Road, London E1 4NS, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Barts and The London, Retroscreen Virology Ltd, Queen Mary’s School of Medicine and Dentistry, 327 Mile End Road, London E1 4NS</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Balasingam, Shobana" sort="Balasingam, Shobana" uniqKey="Balasingam S" first="Shobana" last="Balasingam">Shobana Balasingam</name>
<affiliation wicri:level="1"><nlm:aff id="d297587e98">Barts and The London, Retroscreen Virology Ltd, Queen Mary’s School of Medicine and Dentistry, 327 Mile End Road, London E1 4NS, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Barts and The London, Retroscreen Virology Ltd, Queen Mary’s School of Medicine and Dentistry, 327 Mile End Road, London E1 4NS</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lambkin, Rob" sort="Lambkin, Rob" uniqKey="Lambkin R" first="Rob" last="Lambkin">Rob Lambkin</name>
<affiliation wicri:level="1"><nlm:aff id="d297587e98">Barts and The London, Retroscreen Virology Ltd, Queen Mary’s School of Medicine and Dentistry, 327 Mile End Road, London E1 4NS, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Barts and The London, Retroscreen Virology Ltd, Queen Mary’s School of Medicine and Dentistry, 327 Mile End Road, London E1 4NS</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">14688047</idno>
<idno type="pmc">7110053</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110053</idno>
<idno type="RBID">PMC:7110053</idno>
<idno type="doi">10.1093/jac/dkh037</idno>
<date when="2004">2004</date>
<idno type="wicri:Area/Pmc/Corpus">000B68</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000B68</idno>
<idno type="wicri:Area/Pmc/Curation">000B68</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000B68</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community</title>
<author><name sortKey="Oxford, John" sort="Oxford, John" uniqKey="Oxford J" first="John" last="Oxford">John Oxford</name>
<affiliation wicri:level="1"><nlm:aff id="d297587e98">Barts and The London, Retroscreen Virology Ltd, Queen Mary’s School of Medicine and Dentistry, 327 Mile End Road, London E1 4NS, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Barts and The London, Retroscreen Virology Ltd, Queen Mary’s School of Medicine and Dentistry, 327 Mile End Road, London E1 4NS</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Balasingam, Shobana" sort="Balasingam, Shobana" uniqKey="Balasingam S" first="Shobana" last="Balasingam">Shobana Balasingam</name>
<affiliation wicri:level="1"><nlm:aff id="d297587e98">Barts and The London, Retroscreen Virology Ltd, Queen Mary’s School of Medicine and Dentistry, 327 Mile End Road, London E1 4NS, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Barts and The London, Retroscreen Virology Ltd, Queen Mary’s School of Medicine and Dentistry, 327 Mile End Road, London E1 4NS</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lambkin, Rob" sort="Lambkin, Rob" uniqKey="Lambkin R" first="Rob" last="Lambkin">Rob Lambkin</name>
<affiliation wicri:level="1"><nlm:aff id="d297587e98">Barts and The London, Retroscreen Virology Ltd, Queen Mary’s School of Medicine and Dentistry, 327 Mile End Road, London E1 4NS, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Barts and The London, Retroscreen Virology Ltd, Queen Mary’s School of Medicine and Dentistry, 327 Mile End Road, London E1 4NS</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of Antimicrobial Chemotherapy</title>
<idno type="ISSN">0305-7453</idno>
<idno type="eISSN">1460-2091</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><title>Abstract</title>
<p>Influenza A and B viruses cause serious medical problems and social disruption every year in particular countries of the world. The virus is notoriously fickle and may attack citizens in say two adjacent countries but not the third. More rarely a global pandemic virus emerges causing millions of deaths worldwide. The SARS outbreak has illuminated weaknesses in planning for sudden outbreaks of disease in a modern society and in particular how panic can grip and cause intense economic disruption. Many communities in the world are neither prepared for a global pandemic nor a very acute epidemic of influenza. The neuraminidase inhibitors (NAIs) are a new class of antiviral drug targeting a viral influenza enzyme, the neuraminidase, which acts both to facilitate virus infection of cells by clearing a passage through otherwise protective respiratory fluids and also by helping release of the virus by cutting the chemical umbilical cord which links up the virus to the infected cell. Extensive laboratory studies of the two molecules zanamivir and oseltamivir have shown that they block all influenza A and B viruses yet tested and would, in theory, even inhibit the 1918 pandemic virus. Both drugs can be used prophylactically to prevent spread of infection in families and communities where 80–90% protection has been documented. The therapeutic effects are also strong in adults and children abbreviating infection, reducing quantities of excreted virus and reducing antibiotic prescriptions. The drugs have to be taken within 48 h of the onset of symptoms. Drug resistance is not a problem at present because although such mutants occur the mutants are compromised and are less virulent than their drug-sensitive parents and they spread less easily. The two drugs could be stockpiled to prepare for an influenza pandemic but, importantly, clinical and scientific experience need to be gained by using these inhibitors in the yearly conflagrations of epidemic influenza, which unchecked do great harm to our communities.</p>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<pmc article-type="other"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Antimicrob Chemother</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Antimicrob. Chemother</journal-id>
<journal-id journal-id-type="hwp">jac</journal-id>
<journal-id journal-id-type="publisher-id">jac</journal-id>
<journal-title-group><journal-title>Journal of Antimicrobial Chemotherapy</journal-title>
</journal-title-group>
<issn pub-type="ppub">0305-7453</issn>
<issn pub-type="epub">1460-2091</issn>
<publisher><publisher-name>Oxford University Press</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">14688047</article-id>
<article-id pub-id-type="pmc">7110053</article-id>
<article-id pub-id-type="other">dkh037</article-id>
<article-id pub-id-type="doi">10.1093/jac/dkh037</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Leading Articles</subject>
</subj-group>
</article-categories>
<title-group><article-title>A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Oxford</surname>
<given-names>John</given-names>
</name>
<xref ref-type="aff" rid="d297587e98"></xref>
</contrib>
<contrib contrib-type="author"><name><surname>Balasingam</surname>
<given-names>Shobana</given-names>
</name>
<xref ref-type="aff" rid="d297587e98"></xref>
</contrib>
<contrib contrib-type="author"><name><surname>Lambkin</surname>
<given-names>Rob</given-names>
</name>
<xref ref-type="aff" rid="d297587e98"></xref>
</contrib>
</contrib-group>
<aff id="d297587e98">Barts and The London, Retroscreen Virology Ltd, Queen Mary’s School of Medicine and Dentistry, 327 Mile End Road, London E1 4NS, UK</aff>
<pub-date pub-type="ppub"><month>2</month>
<year>2004</year>
</pub-date>
<pub-date pub-type="epub" iso-8601-date="2004-02-01"><month>2</month>
<year>2004</year>
</pub-date>
<volume>53</volume>
<issue>2</issue>
<fpage>133</fpage>
<lpage>136</lpage>
<permissions><copyright-statement>The British Society for Antimicrobial Chemotherapy</copyright-statement>
<copyright-year>2004</copyright-year>
<license><license-p>This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.</license-p>
</license>
</permissions>
<self-uri xlink:href="dkh037.pdf"></self-uri>
<abstract><title>Abstract</title>
<p>Influenza A and B viruses cause serious medical problems and social disruption every year in particular countries of the world. The virus is notoriously fickle and may attack citizens in say two adjacent countries but not the third. More rarely a global pandemic virus emerges causing millions of deaths worldwide. The SARS outbreak has illuminated weaknesses in planning for sudden outbreaks of disease in a modern society and in particular how panic can grip and cause intense economic disruption. Many communities in the world are neither prepared for a global pandemic nor a very acute epidemic of influenza. The neuraminidase inhibitors (NAIs) are a new class of antiviral drug targeting a viral influenza enzyme, the neuraminidase, which acts both to facilitate virus infection of cells by clearing a passage through otherwise protective respiratory fluids and also by helping release of the virus by cutting the chemical umbilical cord which links up the virus to the infected cell. Extensive laboratory studies of the two molecules zanamivir and oseltamivir have shown that they block all influenza A and B viruses yet tested and would, in theory, even inhibit the 1918 pandemic virus. Both drugs can be used prophylactically to prevent spread of infection in families and communities where 80–90% protection has been documented. The therapeutic effects are also strong in adults and children abbreviating infection, reducing quantities of excreted virus and reducing antibiotic prescriptions. The drugs have to be taken within 48 h of the onset of symptoms. Drug resistance is not a problem at present because although such mutants occur the mutants are compromised and are less virulent than their drug-sensitive parents and they spread less easily. The two drugs could be stockpiled to prepare for an influenza pandemic but, importantly, clinical and scientific experience need to be gained by using these inhibitors in the yearly conflagrations of epidemic influenza, which unchecked do great harm to our communities.</p>
</abstract>
<kwd-group kwd-group-type="KWD"><kwd>Keywords: antivirals, pandemics, epidemics, respiratory viruses</kwd>
</kwd-group>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B68 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000B68 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Pmc |étape= Curation |type= RBID |clé= PMC:7110053 |texte= A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:14688047" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |